Skip to main content
main-content

Semaglutide for weight loss

Results from the STEP and SELECT trials

What you need to know

The weekly injectable GLP-1 receptor agonist semaglutide is approved for use in type 2 diabetes at a dose optimized for glucose lowering, of 1.0 mg/week. But the results of the first STEP trial show that at a higher dose of 2.4 mg/week it is also an effective weight loss agent, easily surpassing the effects of any currently available medication.


Browse this page for details of the completed and ongoing STEP trials, and the SELECT cardiovascular outcomes study, plus interviews with the researchers.

At a glance

Read our round-up of the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.

View the quick guide here

STEP 1 trial results

STEP 2 trial results

STEP 3 trial results

STEP 4 trial results

STEP 6 trial results

02-07-2022 | Semaglutide | News

STEP 6: Semaglutide addresses ‘pathophysiology of metabolic syndrome’ in east Asians

The STEP 6 findings reveal significant weight loss, along with a reduction in abdominal visceral fat, in east Asian people with obesity taking a high dose of semaglutide.

STEP 8 trial results

01-11-2022 | Semaglutide | News

STEP 8: Semaglutide better than liraglutide at weight-management doses

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

approvalsWatch

June 5, 2021: The US FDA has approved the 2.4 mg weekly dose of semaglutide to treat obesity regardless of the presence of type 2 diabetes.

Read more

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox